Open AccessCarcinoembryonic Antigen and Nonspecific Cross‐reacting Antigen in Medullary Carcinoma of the Thyroid
Author(s) -
Kakudo Kennichi,
Takami Hiroshi,
Katayama Shoichi,
Matsuura Nariaki,
Kamoshida Shingo,
Miyauchi Akira,
Watanabe Keiichi
Publication year - 1990
Publication title -
acta patholigica japonica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
ISSN - 0001-6632
DOI - 10.1111/j.1440-1827.1990.tb01560.x
Subject(s) - carcinoembryonic antigen , monoclonal antibody , pathology , epitope , antigen , polyclonal antibodies , oncofetal antigen , antibody , immunohistochemistry , medullary carcinoma , chemistry , paraformaldehyde , thyroid , staining , monoclonal , thyroid carcinoma , antiserum , microbiology and biotechnology , medicine , biology , cancer , immunology , tumor associated antigen
Carcinoembryonic antigen (CEA) and nonspecific cross‐reacting antigen (NCA) were studied immunohisto‐chemically in formalin fixed, paraffin embedded tissues of 73 cases of medullary carcinoma of the thyroid (MTC) using 2 polyclonal antibodies (CEA antisera cross‐reactive with or without NCA), 3 monoclonal antibodies recognizing epitopes only on CEA, and one monoclonal antibody against NCA. The staining patterns of the 5 antibodies against CEA in MTCs were not different, and they reacted with 86.3% of all cases. With regard to the effects of fixatives on the staining patterns, samples fixed with formalin or 4% paraformaldehyde demonstrated CEA immunoreactivity in both the cell membrane and cytoplasm. In Bouin fixed tissue, the immunoreactivity was predominant on the cell membrane, whereas cytoplasmic positivity predominated in alcohol fixed specimens. Thus the difference in fixatives used in previous studies does not appear to be a major reason for the difference in the reported incidence of CEA positive MTCs. It is concluded that CEA is still a useful tumor marker for MTC and that it is detectable only in thyroid tumors originating from C cells, as seen in our series. The epitope defined by monoclonal antibody F106 88, present only on NCA, was found in 42.5% of all cases (49.2% of CEA positive MTCs). The NCA immunoreactivity was located in the tumor cell cytoplasm as globular aggregates, which were also labeled for CEA.